Latest Research
All publications from the Cancer3.AI database, newest first.
[Immunotherapy and Targeted Therapy for Advanced Biliary Tract Cancer].
Lee I, et al
This review examines the rapidly evolving treatment landscape for advanced biliary tract cancer (BTC), a heterogeneous and aggressive group of malignancies — including intrahepatic and extrahepatic cholangiocarcinoma and gallbladder cancer — that carries a poor prognosis and has historically been treated with gemcitabine plus cisplatin chemotherapy as the standard of care for over a decade. The review highlights how immune checkpoint inhibitors targeting PD-1 and PD-L1, particularly when combined with cytotoxic chemotherapy, are demonstrating clinically meaningful benefit and are increasingly being adopted as first-line treatment options for advanced BTC. Comprehensive molecular profiling has uncovered actionable genomic alterations in subsets of patients, including FGFR2 fusions, IDH1 mutations, and HER2 amplification, paving the way for precision-targeted therapies that can be matched to individual tumor biology. Despite these advances, therapeutic responses to both immunotherapy and targeted agents remain highly variable, and validated predictive biomarkers to guide patient selection have not yet been established. The authors conclude that integrating molecular and immunologic tumor profiling is now a critical priority to optimize personalized treatment strategies and improve survival outcomes for patients with this difficult-to-treat cancer.
The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
Source →Retraction Note: Impact of Obstructive Jaundice and Socioeconomic Determinants on Outcomes in Gallbladder Cancer: A Prospective Cohort Study.
Vineet K, et al
This publication is a formal retraction notice issued by the Journal of Gastrointestinal Cancer, withdrawing a previously published prospective cohort study that examined the impact of obstructive jaundice and socioeconomic factors on outcomes in patients with gallbladder cancer. The original study had investigated how bile duct blockage caused by tumors and patients' socioeconomic background influenced survival and clinical outcomes in this aggressive malignancy. No abstract or specific reason for retraction was provided in the available record, meaning the exact grounds for withdrawal remain unclear from this source alone. Retractions are a critical part of the scientific integrity process, signaling that findings from the original article should no longer be relied upon by clinicians or researchers until further clarification is provided. Gallbladder cancer remains a serious and often late-diagnosed disease, and the retraction of research in this area underscores the importance of rigorous methodology and transparent reporting in oncology studies.
Journal of gastrointestinal cancer
Source →Updated Epidemiology of Gastrointestinal Cancers in the Asia-Pacific: Evidence From GBD 2021 and GLOBOCAN 2022.
Tothanarungroj P, et al
A comprehensive review of gastrointestinal (GI) cancer epidemiology across the Asia-Pacific region analyzed data from two major global databases — the Global Burden of Disease 2021 and GLOBOCAN 2022 — to assess age-standardized incidence and death rates for cancers of the colon, rectum, stomach, liver, esophagus, pancreas, and gallbladder. Colorectal cancer emerged as the most commonly diagnosed GI cancer across all Asia-Pacific subregions in both datasets, while mortality patterns varied considerably by geography. Mongolia showed a disproportionately high burden of esophageal, gastric, and liver cancers, whereas Japan and Australia faced substantial rates of colorectal and pancreatic cancers, with Japan also carrying a significant gastric cancer burden. Cancers with established screening programs — such as colorectal and gastric cancer — showed lower mortality-to-incidence ratios, suggesting that early detection through screening meaningfully reduces cancer deaths, while esophageal, pancreatic, and gallbladder cancers carried near-equal incidence and death rates, reflecting their poor prognosis and the absence of cost-effective early-detection tools. Several lower-income countries in South-East Asia and the Pacific Islands reported unusually low rates, likely attributable to gaps in cancer registry infrastructure rather than a truly low disease burden. These findings underscore the urgent need for strengthened national cancer registries, targeted screening initiatives, and tailored health policies across the diverse Asia-Pacific region to reduce the growing GI cancer burden.
Journal of gastroenterology and hepatology
Source →Genomic landscape and clinicopathological predictors of survival in gallbladder cancer.
Pandey M, et al
A new study from North India examined the genetic and clinical profiles of 35 gallbladder cancer patients to uncover factors driving the region's exceptionally poor patient outcomes. Using targeted next-generation sequencing alongside clinical data and Python-based survival analysis pipelines, researchers documented a striking 97% mortality rate and a median survival of only seven months, largely because 80% of patients presented with advanced-stage disease at diagnosis. The most frequently detected genetic mutations involved TP53 (31.4%) and KRAS (14.3%), and while overall mutation burden did not significantly affect overall survival, KRAS mutations showed a strong trend toward a more than seven-fold increased risk of cancer recurrence. Elevated CA19-9 blood tumor marker levels and patient age above 40 years emerged as the strongest independent predictors of death in multivariate analysis. These findings highlight the urgent need for earlier detection strategies and region-specific genomic screening programs, since late-stage presentation rather than mutation profile appears to be the primary driver of mortality in this high-burden population. The authors argue that precision oncology approaches tailored to the distinct genetic landscape of North Indian gallbladder cancer patients could meaningfully improve clinical outcomes.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Source →Establishment of Salivary Gland Tumors Arising in Salivary Gland-Specific EWSR1::ATF1 Transgenic Mice.
Hirai Y, et al
Researchers have developed genetically engineered mice that express the EWSR1::ATF1 fusion gene specifically in salivary gland tissue, creating the first animal model to directly test this gene's role in causing hyalinizing clear cell carcinoma (HCCC), a rare and poorly understood salivary gland cancer. The fusion gene, which arises from a chromosomal translocation between chromosomes 12 and 22, was activated exclusively in salivary gland cells by crossing two transgenic mouse lines using a Cre-lox genetic approach. Malignant tumors developed in the major salivary glands of three of the transgenic mice, and these tumors were analyzed using Western blotting, histopathology, and RNA sequencing to characterize their molecular and cellular properties. Notably, the mouse tumors displayed more aggressive malignant features than typically seen in human HCCC, indicating that EWSR1::ATF1 expression is sufficient to drive salivary gland tumor formation and may contribute to disease severity. These findings provide the first direct in vivo evidence that EWSR1::ATF1 plays a causal role in salivary gland malignancy and establish a preclinical model that could accelerate the discovery of targeted therapies for patients with this rare cancer.
Head & neck
Source →